Trump Administration Ends Medicare Drug Subsidy, Raising Costs for Millions of Seniors

The Trump Administration is ending a major subsidy program that has helped keep prescription drug premiums lower for millions of seniors, a move expected to increase costs for many starting in 2027. This program, which funneled an estimated $3.6 billion to insurers in 2026, will not be renewed, directly impacting about 25 million Americans enrolled in standalone Medicare Part D plans. CMS Administrator Dr. Mehmet Oz defended the decision, stating the market is now stable enough that this 'bailout' is no longer necessary. While the administration suggests many seniors might see minimal changes or even lower premiums, officials also estimate that nearly half of Part D enrollees could face monthly increases between $11 and $20. This shift could push more seniors towards Medicare Advantage plans, which often bundle drug benefits and may offer lower or no monthly premiums. Seniors will find out their exact 2027 premium rates later this fall, ahead of the annual enrollment period. Despite the end of this subsidy, other policies like the Inflation Reduction Act will continue to cap annual premium increases and limit out-of-pocket spending for Part D beneficiaries to $2,400, while the deductible is set to rise to $700. This move underscores an ongoing debate about healthcare affordability and government's role in managing costs for an aging population.